文献速递前列腺增生与排尿功能障碍

基于IPSS排尿/储尿比值的男性下尿路症状药物个体化调整

Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio.
PubMed 文献 · Urology · 2018-07-07

本研究纳入374例轻中度下尿路症状男性,根据基线IPSS排尿/储尿亚评分比值(IPSS-V/S)初始给予多沙唑嗪或托特罗定治疗1个月,再依据IPSS-V/S变化、尿流率和总体反应评估调整用药。结果显示按症状个体化调整药物后各亚组总体反应评估均有显著改善。

要点

  • 基线IPSS-V/S≤1者162例,>1者212例,初始分别用托特罗定或多沙唑嗪。
  • 1个月后两组IPSS总分、储尿评分和IPSS-V/S均显著改善。
  • 根据IPSS-V/S变化调整药物后各亚组总体反应评估均显著改善。

核心结论

  • 初始药物治疗后依据IPSS-V/S调整用药,可为轻中度下尿路症状男性带来满意疗效。

研究设计与样本

  • 研究纳入374例轻中度下尿路症状男性,基线IPSS-V/S≤1者162例、>1者212例。
  • 初始治疗1个月:IPSS-V/S>1者每日多沙唑嗪4mg,IPSS-V/S≤1者每日托特罗定4mg。
  • 随后依据IPSS-V/S变化、尿流率和总体反应评估调整用药,比较基线、治疗后1个月和3个月结果。

主要发现

  • 初始托特罗定的162例中,102例(63.0%)继续单药治疗,20例(12.3%)因IPSS-V/S>1.5改为多沙唑嗪单药,40例(24.7%)因IPSS-V/S>1但≤1.5加用多沙唑嗪。
  • 初始多沙唑嗪的212例中,171例(80.7%)继续单药治疗,9例IPSS-V/S<1.5者换用托特罗定,32例IPSS-V/S<2但>1.5者加用托特罗定。
  • 两组治疗后1个月IPSS总分、储尿评分和IPSS-V/S均显著改善。
  • 按症状调整药物后各亚组总体反应评估均显著改善。

临床怎么用

  • 对轻中度下尿路症状男性,可先按基线IPSS-V/S比值选择α受体阻滞剂或抗胆碱能药物初始治疗。
  • 初始治疗1个月后复查IPSS-V/S、尿流率和总体反应评估,据此个体化调整单药或联合方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate therapeutic results of tailoring medication for lower urinary tract symptoms (LUTS) in men according to initial treatment results and International Prostate Symptom Score (IPSS)-voiding to storage subscore (V/S) ratio. METHODS: Men with mild-to-moderate LUTS were initially treated for 1 month with doxazosin 4 mg daily for IPSS-V/S >1 or tolterodine 4 mg daily for IPSS-V/S ≤1. They then underwent the Global Response Assessment (GRA) to tailor their medication by changes in IPSS-V/S, uroflow, and GRA, which were compared at baseline, 1, and 3 months post-treatment. RESULTS: Upon baseline, 162/374 men had IPSS-V/S ≤1, and 212/374 had an IPSS-V/S >1. Both groups had significant improvement in IPSS-T, IPSS-S, and IPSS-V/S 1 month post-treatment. Of the 162 men initially receiving tolterodine, 102 (63.0%) continued monotherapy; 20 (12.3%) had IPSS-V/S >1.5 and were shifted to doxazosin monotherapy, and 40 (24.7%) had IPSS-V/S >1 but ≤1.5 and added doxazosin. Among the 212 men initially receiving doxazosin, 171 (80.7%) continued monotherapy; 9 with IPSS-V/S <1.5 were switched to tolterodine, and 32 had IPSS-V/S <2 but >1.5 and added tolterodine. Improvement in GRA was remarkable in all subgroups with tailoring the medication to patient symptomatology. CONCLUSION: This study reveals that treatment customization according to IPSS-V/S after initial medical therapy provided satisfactory outcomes for men with mild-to-moderate LUTS.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lee CL, Kuo HC. Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio. Urology. 2018. PMID: 29990572. doi:10.1016/j.urology.2018.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。